Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
NCT ID: NCT00174304
Last Updated: 2021-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1120 participants
INTERVENTIONAL
2004-10-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
NCT00330785
Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia
NCT00174330
A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin
NCT00530946
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
NCT00143234
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
NCT00136942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine/atorvastatin single pill
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Salzburg, , Austria
Pfizer Investigational Site
Sankt Pölten, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Wels, , Austria
Pfizer Investigational Site
Bierbeek, , Belgium
Pfizer Investigational Site
Braine-l'Alleud, , Belgium
Pfizer Investigational Site
Bruges, , Belgium
Pfizer Investigational Site
De Pinte, , Belgium
Pfizer Investigational Site
Gozée, , Belgium
Pfizer Investigational Site
Seraing, , Belgium
Pfizer Investigational Site
Wemmel, , Belgium
Pfizer Investigational Site
Wilrijk, , Belgium
Pfizer Investigational Site
Zedelgem, , Belgium
Pfizer Investigational Site
Helsinki, , Finland
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Oulu, , Finland
Pfizer Investigational Site
Oulu, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Turku, , Finland
Pfizer Investigational Site
Turku, , Finland
Pfizer Investigational Site
Vantaa, , Finland
Pfizer Investigational Site
Heraklion, Crete, Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Ioannina, , Greece
Pfizer Investigational Site
Larissa, , Greece
Pfizer Investigational Site
Melíssia, , Greece
Pfizer Investigational Site
Pireaus, , Greece
Pfizer Investigational Site
Rio, Patra, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Debrecen, , Hungary
Pfizer Investigational Site
Kecskemét, , Hungary
Pfizer Investigational Site
Miskolc, , Hungary
Pfizer Investigational Site
Mosonmagyaróvár, , Hungary
Pfizer Investigational Site
Pécs, , Hungary
Pfizer Investigational Site
Szekszárd, , Hungary
Pfizer Investigational Site
Gorey, Wexford, Ireland
Pfizer Investigational Site
New Ross, Wexford, Ireland
Pfizer Investigational Site
Vimercate, (MI), Italy
Pfizer Investigational Site
Somma Lombardo, (VA), Italy
Pfizer Investigational Site
San Sisto, PG, Italy
Pfizer Investigational Site
Mestre, VE, Italy
Pfizer Investigational Site
Asti, , Italy
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Bolzano, , Italy
Pfizer Investigational Site
Brescia, , Italy
Pfizer Investigational Site
Catania, , Italy
Pfizer Investigational Site
Catania, , Italy
Pfizer Investigational Site
Chieti, , Italy
Pfizer Investigational Site
Ferrara, , Italy
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Foggia, , Italy
Pfizer Investigational Site
Genova, , Italy
Pfizer Investigational Site
Grosseto, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Novara, , Italy
Pfizer Investigational Site
Palermo, , Italy
Pfizer Investigational Site
Palermo, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Potenza, , Italy
Pfizer Investigational Site
Prato, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Salerno, , Italy
Pfizer Investigational Site
Sassari, , Italy
Pfizer Investigational Site
Siena, , Italy
Pfizer Investigational Site
Torino, , Italy
Pfizer Investigational Site
Venezia, , Italy
Pfizer Investigational Site
Guilhufe - PNF, Penafiel, Portugal
Pfizer Investigational Site
Matosinhos Municipality, Sra. Da Hora, Portugal
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Faro, , Portugal
Pfizer Investigational Site
Leiria, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
S. Martinho Do Bispo, , Portugal
Pfizer Investigational Site
Viana do Castelo, , Portugal
Pfizer Investigational Site
Izola, , Slovenia
Pfizer Investigational Site
Ljubljana, , Slovenia
Pfizer Investigational Site
Maribor, , Slovenia
Pfizer Investigational Site
Donostia / San Sebastian, Guipuzcoa, Spain
Pfizer Investigational Site
Reus, Tarragona, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Baden, Canton of Aargau, Switzerland
Pfizer Investigational Site
Basel, Canton of Basel-City, Switzerland
Pfizer Investigational Site
Bern, Canton of Bern, Switzerland
Pfizer Investigational Site
Sankt Gallen, Canton of St. Gallen, Switzerland
Pfizer Investigational Site
Lausanne, Canton of Vaud, Switzerland
Pfizer Investigational Site
Lugano, Canton Ticino, Switzerland
Pfizer Investigational Site
Münsterlingen, Thurgau, Switzerland
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Richard Hobbs FD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, da Silva PM; JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):472-80. doi: 10.1097/HJR.0b013e32832b63f5.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3841029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.